idazoxan has been researched along with Clinically Isolated CNS Demyelinating Syndrome in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, GQ; Chen, JF; Chen, YY; Han, Z; Shang, XF; Shao, B; Wang, XS; Xu, HQ; Yang, HM; Zheng, RY; Zhu, ZG | 1 |
1 other study(ies) available for idazoxan and Clinically Isolated CNS Demyelinating Syndrome
| Article | Year |
|---|---|
Idazoxan attenuates spinal cord injury by enhanced astrocytic activation and reduced microglial activation in rat experimental autoimmune encephalomyelitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Astrocytes; Cerebral Cortex; Cytokines; Demyelinating Diseases; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Gene Expression Regulation; Idazoxan; Imidazoline Receptors; Microglia; Multiple Sclerosis; Neuroprotective Agents; Rats; Rats, Wistar; RNA, Messenger; Spinal Cord | 2009 |